Physician profile
Mark D Fromer
NPI 1164435780
$5,696.83
in general payments reported to CMS, 2019-2025
27 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $282 · 2021: $808 · 2022: $704 · 2023: $1,804 · 2024: $650 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $866.48 | 2019-2022 | |
| Alcon Vision LLC | $849.72 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Lensx |
| New World Medical,INC. | $828.15 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $685.65 | 2019-2023 | |
| Abbvie INC. | $534.97 | 2022-2025 | |
| Oyster Point Pharma, INC. | $233.42 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $206.39 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $159.77 | 2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $142.62 | 2022-2024 | Eylea Hd |
| Aerie Pharmaceuticals, INC. | $130.51 | 2019 | |
| Biogen, INC. | $124.40 | 2022 | |
| Coopervision INC. | $122.25 | 2023-2024 | Paragon Crt, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $104.69 | 2021-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $99.59 | 2024 | Star S4 Ir |
| Biotissue Holdings INC. | $93.22 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $89.60 | 2019 | |
| Shire North American Group INC | $67.39 | 2019 | |
| Bausch & Lomb Americas INC. | $58.50 | 2022 | |
| Amgen INC. | $48.65 | 2024 | Tepezza |
| Beaver-Visitec International, INC. | $48.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $39.90 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $31.05 | 2024 | Xdemvy |
| Astellas Pharma US INC | $30.73 | 2023 | |
| Genentech USA, INC. | $25.38 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.95 | 2019 | |
| Horizon Therapeutics Plc | $17.05 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fromer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.